ERBB2 and breast cancer: EVs have been shown to interfere with antibody therapy in human epidermal growth factor receptor‐2 (HER‐2) overexpressing breast cancers, where the removal of HER‐2‐positive EVs was proposed to improve therapeutic outcomes.24